Summary
Deschloroetizolam, sometimes referred to as Etizolam-2, is a thienotriazolodiazepine compound, and it represents the dechlorinated counterpart of the closely associated etizolam. This chemical has been marketed and sold as a designer drug.
| Identifiers | |
|---|---|
| IUPAC name | |
| CAS Number | 40054-73-7 |
|---|---|
| PubChem CID | 827322 |
| ChemSpider | 722596 |
| UNII | 69HF7J354D |
| Chemical and physical data | |
| Formula | C17H16N4S |
| Molar mass | 308.40 g·mol−1 |
Legal status
As of October 15, 2015, Sweden has designated Deschloroetizolam as a regulated hazardous substance.
FAQ
1. What is Deschloroetizolam?
Deschloroetizolam is a chemical compound classified as a thienotriazolodiazepine and is closely related to etizolam. It is often used as a designer drug and has psychoactive properties.
2. Is Deschloroetizolam legal?
The legal status of Deschloroetizolam varies from one region to another. In many places, it falls under regulations related to controlled substances or designer drugs. It’s essential to be aware of the specific laws in your area.
3. What are the potential effects of Deschloroetizolam?
Deschloroetizolam is known for its sedative and anxiolytic effects. Users may experience a sense of relaxation, reduced anxiety, and calming effects. However, it can also lead to drowsiness and memory impairments.
4. Are there any risks associated with Deschloroetizolam use?
Yes, there are risks involved in using Deschloroetizolam, including the potential for addiction, overdose, and side effects. Combining it with other substances, especially depressants like alcohol, can be extremely dangerous.
5. Is Deschloroetizolam addictive?
As with many benzodiazepine derivatives, Deschloroetizolam has the potential for physical and psychological dependence if used regularly or in high doses. Withdrawal symptoms may occur if use is abruptly discontinued.
6. Can Deschloroetizolam be used for medical purposes?
Deschloroetizolam is not approved for medical use in most countries. It is primarily used recreationally and as a designer drug.
7. How can I stay safe when using Deschloroetizolam?
If you choose to use Deschloroetizolam, prioritize safety. Start with a low dose, avoid combining it with other substances, and be cautious about frequency of use. Always be aware of the legal status in your area and consider potential health risks.
8. Is Deschloroetizolam detectable in drug tests?
Standard drug tests do not typically screen for Deschloroetizolam. However, specialized tests may be able to detect its presence. If you are concerned about drug testing, it’s best to abstain from using it.
9. Can Deschloroetizolam be purchased online?
Deschloroetizolam is sometimes available through online sources or darknet vendors. However, the legality of purchasing it online varies by location, and buying unregulated substances online carries inherent risks.
10. Is Deschloroetizolam safe for everyone to use?
No, Deschloroetizolam may not be safe for everyone. Individuals with a history of substance abuse, certain medical conditions, or those taking other medications should exercise caution and consult with a healthcare professional before using it.
11. What should I do if I or someone I know is struggling with Deschloroetizolam use?
If you or someone you know is experiencing problems related to Deschloroetizolam use, it is essential to seek help from a healthcare professional or addiction specialist. Addiction and substance abuse can have serious consequences, and support is available.
References
- Weber KH, Bauer A, Langbein A, and Daniel H made significant strides in September 1978, as they explored “Heteroaromaten mit anellierten Siebenringen, III. Umwandlung von Thienotriazolooxazepinen in Diazepine” in the renowned scientific journal Justus Liebigs Annalen der Chemie (in German). Their research, cataloged in 1978 (8): 1257–1265, made a notable contribution to the field. This work can be revisited with a DOI of 10.1002/jlac.197819780806.
- US 3904641, authored by Nakanishi M, Tahara T, Araki K, and Shiroki M and published on September 9, 1975, marked a significant milestone. This patent, titled “Triazolothienodiazepine compounds,” was assigned to Yoshitomi Pharmaceutical Industries, Ltd.
- EP 0776892, with contributions from Hiroshi K, Syuji E, Hideaki S, Minoru M, and Kenichi O, was published on June 4, 1997. This patent, titled “Thienylazole compound and thienotriazolodiazepine compound,” was also assigned to Yoshitomi Pharmaceutical Industries, Ltd.
- The “Deschloroetizolam” entry in the New Synthetic Drugs Database represents a valuable resource for those seeking information on this compound.
- Pettersson Bergstrand M, Helander A, Hansson T, and Beck O, in their April 2017 study, delved into the “Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.” This research, found in Drug Testing and Analysis (Volume 9, Issue 4, Pages 640–645), contributed to the understanding of benzodiazepine detectability in various screening assays. The research can be accessed with a DOI of 10.1002/dta.2003 and PMID 27366870.
- In March 2018, Manchester KR, Maskell PD, and Waters L tackled the topic of “Experimental versus theoretical log D7.4, pKa, and plasma protein binding values for benzodiazepines appearing as new psychoactive substances” in Drug Testing and Analysis (Volume 10, Issue 8, Pages 1258–1269). This research, with a DOI of 10.1002/dta.2387, PMID 29582576, and S2CID 31098917, added a layer of depth to our understanding of new psychoactive substances.
- In July 2022, Manchester KR, Waters L, Haider S, and Maskell PD shed light on “The blood-to-plasma ratio and predicted GABAA-binding affinity of designer benzodiazepines” in Forensic Toxicology (Volume 40, Issue 2, Pages 349–356). This research, with a DOI of 10.1007/s11419-022-00616-y, PMC 9715504, PMID 36454409, and S2CID 247455284, furthered our knowledge in the realm of designer benzodiazepines.
- The “Nya substanser klassas som narkotika eller hälsofarlig vara” (in Swedish) update by Folkhälsomyndigheten on August 18, 2015, highlighted the classification of new substances as narcotics or hazardous products, contributing to the regulation of such compounds.